VINEETLAB
Vineet Laboratories financials
- Market cap
- ₹69 Cr
- Sector
- Healthcare
What Vineet Laboratories Limited does
Vineet Laboratories Limited manufactures pharmaceutical intermediates and fine chemicals at its own factory. The company is ISO 9001:2015 certified and is recognised for its capabilities in product development and process technology. It operates as an outsourcing partner, supplying these intermediates and fine chemicals to multinational pharmaceutical companies that source their requirements from it.
- Manufacturing facility
- 1 (own factory, referenced in FY2024-25 report)
- Quality certification
- ISO 9001:2015
Quarterly results
Q4 FY26: revenue up 34.2%, net profit up 106.9% against the same quarter last year.
| Line item | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 24 | 19 | 18 | 14 | 7 −69% | 17 −8% | 16 −14% | 19 +34% |
| EBITDA | -1 | -0 | -4 | -11 | 0 +139% | 3 +1126% | 2 +160% | 2 +123% |
| Net profit | -2 | -2 | -6 | -11 | -1 +59% | 0 +122% | 1 +115% | 1 +107% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +7.0% 1Y
1Y: ₹34.6 on 10 Sept 2025 → ₹37.02. High ₹47.87 (30 Oct 2025), low ₹29.01 (17 Mar 2026).
Financials, as filed
Revenue fell 37.2% a year over 2 years, FY24 to FY26. Operating margin widened to 14.2%.
| Year ending | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹151 Cr | ₹75 Cr | ₹59 Cr |
| Operating profit | ₹7 Cr | ₹-16 Cr | ₹8 Cr |
| Operating margin | 4.8% | -21.7% | 14.2% |
| Interest | ₹5 Cr | ₹4 Cr | ₹5 Cr |
| Depreciation | ₹3 Cr | ₹3 Cr | ₹2 Cr |
| Net profit | ₹1 Cr | ₹-20 Cr | ₹1 Cr |
| Net margin | 0.7% | -26.9% | 1.9% |
| Cash from operations | ₹-7 Cr | ₹11 Cr | — |
| Free cash flow | ₹-9 Cr | ₹10 Cr | — |
| ROCE | 6.7% | -27.9% | 8.5% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Equity capital | ₹0 Cr | ₹9 Cr | ₹9 Cr | ₹9 Cr | ₹9 Cr | ₹9 Cr |
| Reserves | ₹-0 Cr | ₹17 Cr | ₹24 Cr | ₹24 Cr | ₹26 Cr | ₹5 Cr |
| Borrowings | ₹0 Cr | ₹12 Cr | ₹27 Cr | ₹31 Cr | ₹44 Cr | ₹43 Cr |
| Other liabilities | ₹0 Cr | ₹70 Cr | ₹74 Cr | ₹51 Cr | ₹38 Cr | ₹34 Cr |
| Total liabilities | ₹0 Cr | ₹109 Cr | ₹133 Cr | ₹116 Cr | ₹117 Cr | ₹91 Cr |
| Fixed assets | ₹0 Cr | ₹20 Cr | ₹21 Cr | ₹27 Cr | ₹27 Cr | ₹24 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹0 Cr | ₹89 Cr | ₹112 Cr | ₹89 Cr | ₹90 Cr | ₹66 Cr |
| Total assets | ₹0 Cr | ₹109 Cr | ₹133 Cr | ₹116 Cr | ₹117 Cr | ₹91 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, promoters trimmed −23.28 pp while the public added +22.78 pp.
- Promoters
- 6.0%
- FIIs
- 0.5%
- Public
- 93.5%
Since Jun 2025
- Promoters −23.28 pp
- Public +22.78 pp
- FIIs +0.50 pp
How it drifted, 12 quarters
Over this window promoters fell from 38.7% to 6.0% — −32.7 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 38.7%, Public 61.3%.Dec '23: Promoters 37.5%, FIIs 0.2%, Public 62.2%.Mar '24: Promoters 37.5%, Public 62.5%.Jun '24: Promoters 37.5%, Public 62.5%.Sep '24: Promoters 36.1%, Public 63.9%.Dec '24: Promoters 35.9%, Public 64.2%.Mar '25: Promoters 35.9%, Public 64.2%.Jun '25: Promoters 29.3%, Public 70.7%.Sep '25: Promoters 15.9%, Public 84.1%.Dec '25: Promoters 12.5%, Public 87.5%.Mar '26: Promoters 6.0%, FIIs 0.4%, Public 93.7%.Jun '26: Promoters 6.0%, FIIs 0.5%, Public 93.5%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Madhu Nalajala +1.07 pp 2.40% held
The same filing shows 0 holders trimming and 2 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Vineet Laboratories Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Arjun Aggarwal | 11.35% | unchanged |
| Gaddam Venkata Ramana | 2.46% | unchanged |
| Madhu Nalajala | 2.40% | +1.07 pp |
| Rajesh Poddar | 2.15% | unchanged |
| Palloli Rama Chandra Reddy | 1.86% | unchanged |
| Iswarya Gajjala | 1.62% | unchanged |
| Sudha Madhu Sudhan Reddy | 1.61% | unchanged |
| Anasuya Gorla | 1.58% | unchanged |
| Rajendra Agarwal | 1.57% | unchanged |
| Ajay Agrawal | 1.53% | unchanged |
| Surekha Naga Lakshmi Pendela | 1.51% | unchanged |
| Jyoti Agarwal | 1.39% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Vineet Laboratories Limited
Guides on how to read this kind of business and the numbers that matter.